--- name: liquid-biopsy-analytics-agent description: "---name: liquid-biopsy-analytics-agent description: AI-powered comprehensive liquid biopsy analysis integrating ctDNA, CTCs, exosomes, and cfRNA for cancer detection, monitoring, and treatment guidance. license: MIT metadata: author: AI Group version: \"1.0.0\" created: \"2026-01-19\" compatibility:" --- --- name: 'liquid-biopsy-analytics-agent' description: 'Comprehensive analysis of liquid biopsy data (ctDNA, CTCs) for cancer detection, MRD monitoring, and response tracking.' keywords: - liquid-biopsy - ctdna - mrd - cancer-detection - treatment-response measurable_outcome: 'Detects circulating tumor DNA with 0.01% sensitivity and accurately predicts treatment response in longitudinal samples.' allowed-tools: - read_file - run_shell_command --- # Liquid Biopsy Analytics Agent The **Liquid Biopsy Analytics Agent** provides comprehensive AI-driven analysis of blood-based cancer biomarkers. It integrates circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free RNA for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and treatment response assessment. ## When to Use This Skill * For multi-cancer early detection screening from blood samples. * To monitor minimal residual disease (MRD) after curative treatment. * When tracking tumor evolution and resistance during therapy. * For real-time treatment response assessment. * To detect cancer recurrence before clinical or imaging evidence. ## Core Capabilities 1. **ctDNA Mutation Analysis**: Variant calling, VAF tracking, and clonal evolution from cell-free DNA. 2. **Methylation-Based Detection**: cfDNA methylation patterns for cancer detection and tissue-of-origin identification. 3. **CTC Enumeration & Analysis**: AI-powered CTC detection, enumeration, and molecular characterization. 4. **Multi-Modal Integration**: Combines ctDNA, CTCs, and protein biomarkers with clinical/imaging data. 5. **MRD Monitoring**: Ultra-sensitive detection of residual disease post-treatment. 6. **Response Prediction**: AI models predicting treatment response from longitudinal liquid biopsy data. ## Analyte Types and Applications | Analyte | Detection Method | Clinical Use | |---------|------------------|--------------| | ctDNA mutations | NGS, ddPCR | Therapy selection, resistance | | ctDNA methylation | WGBS, targeted | MCED, tissue of origin | | ctDNA fragmentation | WGS | Cancer detection | | CTCs | CellSearch, microfluidics | Prognosis, monitoring | | Exosomes | Immunocapture | Biomarker cargo | | cfRNA | RT-qPCR, NGS | Gene expression | ## Workflow 1. **Input**: Liquid biopsy data (ctDNA variants, methylation, CTC counts, protein markers). 2. **Quality Control**: Assess sample quality, input DNA amount, background noise. 3. **Variant Analysis**: Call mutations, calculate VAF, filter artifacts (CHIP). 4. **Multi-analyte Integration**: Combine biomarker signals using ML fusion. 5. **Clinical Interpretation**: Generate actionable insights for treatment decisions. 6. **Longitudinal Tracking**: Model dynamics for response assessment and recurrence detection. 7. **Output**: Cancer detection probability, MRD status, treatment recommendations, clonal evolution. ## Example Usage **User**: "Analyze longitudinal ctDNA data from this lung cancer patient to assess treatment response and detect resistance." **Agent Action**: ```bash python3 Skills/Oncology/Liquid_Biopsy_Analytics_Agent/lb_analyzer.py \ --ctdna_variants longitudinal_ctdna.vcf \ --timepoints week0,week4,week8,week12 \ --tumor_markers cea_values.csv \ --baseline_tissue baseline_tumor.maf \ --analysis response_resistance \ --chip_filter true \ --output lb_report/ ``` ## AI/ML Models **Multi-Cancer Early Detection (MCED)**: - Methylation-based classifiers (sensitivity ~50-80% at 99% specificity) - Multi-analyte combination models - Tissue-of-origin prediction - Integration with imaging and clinical risk **MRD Detection**: - Tumor-informed (personalized panels from tissue) - Tumor-agnostic (fixed panels, methylation) - Detection limits: 0.01% - 0.001% VAF **Response Prediction**: - Longitudinal VAF dynamics modeling - Bayesian evolution frameworks - Time-to-progression prediction ## Clonal Hematopoiesis Filtering Critical challenge in liquid biopsy interpretation: | Gene | Prevalence | Action | |------|------------|--------| | DNMT3A | 30-40% of CHIP | Filter if VAF stable, no tumor context | | TET2 | 20-30% | Filter if VAF stable | | ASXL1 | 10-15% | Filter if VAF stable | | TP53 | 5-10% | Context-dependent (tumor vs CHIP) | | Matched WBC | Gold standard | Subtract germline/CHIP variants | ## Commercial Platforms (Reference) | Platform | Technology | Application | |----------|------------|-------------| | Guardant360 | ctDNA NGS | Therapy selection | | FoundationOne Liquid | ctDNA NGS | Comprehensive profiling | | Galleri | Methylation | MCED screening | | Signatera | Tumor-informed | MRD monitoring | | CellSearch | CTC | FDA-cleared enumeration | ## Clinical Decision Points 1. **Treatment Selection**: Actionable mutations (EGFR, ALK, ROS1, BRAF) 2. **Response Assessment**: ctDNA clearance correlates with outcomes 3. **Resistance Detection**: Emerging resistance mutations (T790M, C797S) 4. **Recurrence Monitoring**: Lead time of 3-6 months over imaging ## Prerequisites * Python 3.10+ * NGS variant calling pipelines * Methylation analysis tools * Machine learning frameworks ## Related Skills * ctDNA_Analysis - For detailed ctDNA workflows * Tumor_Clonal_Evolution - For evolutionary analysis * MRD_Detection - For residual disease focus ## Limitations and Considerations - **False positives**: CHIP, benign tumors, inflammation - **False negatives**: Low shedding tumors, early stage - **Technical variability**: Pre-analytical factors critical - **Cost**: Multi-analyte panels expensive ## Author AI Group - Biomedical AI Platform --- Source attribution: mdbabumiamssm Original project: https://github.com/mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-/blob/ef3c40b235ba23083e67263a921759784f0dd251/Skills/Oncology/Liquid_Biopsy_Analytics_Agent/SKILL.md License: MIT License information: https://opensource.org/license/mit Original upstream instructions; downloaded from Dave AI. ## Upstream license notice MIT License Copyright (c) 2025 MD BABU MIA , PHD Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the "Software"), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions: The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software. THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE. # Dave AI resource metadata Creator / publisher: mdbabumiamssm Original project: https://github.com/mdbabumiamssm/LLMs-Universal-Life-Science-and-Clinical-Skills-/blob/ef3c40b235ba23083e67263a921759784f0dd251/Skills/Oncology/Liquid_Biopsy_Analytics_Agent/SKILL.md Attribution basis: Recovered original package and original project license at a pinned revision Fields of work: Data & Analytics, Healthcare & Life Sciences Roles: Business Intelligence Analyst, Clinical Research, Data Scientist, Health Informatics, Medical Writer Specialties: API, Backend, Testing Tools: Python Country applicability: Country not specified Classification basis: Source catalog labels Instruction SHA-256: c3ade2a2e7d7e1f02c55a2d6682027ec772e71c3e03b8acbc5891738b68be116 Metadata reviewed: 2026-10-27 This metadata supersedes earlier Dave AI catalog attribution. Original instruction and supporting files are preserved.